Bd selects "embecta" as name of new company for planned spinoff of diabetes care business; announces remainder of leadership team

Franklin lakes, n.j., dec. 6, 2021 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced that "embecta" [pronounced em-beck-tah] will be the name of the independent, publicly-traded company that will hold bd's diabetes care business upon the completion of the previously announced spinoff, which is expected to close in the second quarter of calendar year 2022.
BDX Ratings Summary
BDX Quant Ranking